These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29241341)

  • 21. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.
    Miller PD; Hattersley G; Lau E; Fitzpatrick LA; Harris AG; Williams GC; Hu MY; Riis BJ; Russo L; Christiansen C
    Bone; 2019 Mar; 120():137-140. PubMed ID: 30359763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Handling Parathormone Receptor Type 1 in Skeletal Diseases: Realities and Expectations of Abaloparatide.
    Ardura JA; Portal-Núñez S; Alonso V; Bravo B; Gortazar AR
    Trends Endocrinol Metab; 2019 Oct; 30(10):756-766. PubMed ID: 31409530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
    Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
    Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.
    Cosman F; Hattersley G; Hu MY; Williams GC; Fitzpatrick LA; Black DM
    J Bone Miner Res; 2017 Jan; 32(1):17-23. PubMed ID: 27612281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
    O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
    Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
    Bilezikian JP; Hattersley G; Mitlak BH; Hu MY; Fitzpatrick LA; Dabrowski C; Miller PD; Papapoulos SE
    Curr Med Res Opin; 2019 Dec; 35(12):2097-2102. PubMed ID: 31418585
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.
    Cosman F; Cooper C; Wang Y; Mitlak B; Varughese S; Williams SA
    Osteoporos Int; 2022 Aug; 33(8):1703-1714. PubMed ID: 35524068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
    Czerwinski E; Cardona J; Plebanski R; Recknor C; Vokes T; Saag KG; Binkley N; Lewiecki EM; Adachi J; Knychas D; Kendler D; Orwoll E; Chen Y; Pearman L; Li YH; Mitlak B
    J Bone Miner Res; 2022 Dec; 37(12):2435-2442. PubMed ID: 36190391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
    Miller PD; Bilezikian JP; Fitzpatrick LA; Mitlak B; McCloskey EV; Cosman F; Bone HG
    Curr Med Res Opin; 2020 Nov; 36(11):1861-1872. PubMed ID: 32969719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.
    Tella SH; Kommalapati A; Correa R
    Cureus; 2017 May; 9(5):e1300. PubMed ID: 28680788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.
    Matsumoto T; Sone T; Soen S; Tanaka S; Yamashita A; Inoue T
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4222-e4231. PubMed ID: 35977548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abaloparatide (Tymlos) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):97-98. PubMed ID: 28609423
    [No Abstract]   [Full Text] [Related]  

  • 35. Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis.
    Winzenrieth R; Humbert L; Boxberger JI; Weiss RJ; Wang Y; Kostenuik P
    J Clin Densitom; 2022; 25(3):392-400. PubMed ID: 35033435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
    Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abaloparatide: First Global Approval.
    Shirley M
    Drugs; 2017 Aug; 77(12):1363-1368. PubMed ID: 28624872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
    Hong P; Liu R; Rai S; Liu J; Zhou Y; Zheng Y; Li J
    J Orthop Surg Res; 2023 Feb; 18(1):116. PubMed ID: 36797767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
    Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
    Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.